![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 25, 2016 6:48:06 PM
Relypsa Inc. (RLYP) announced Phase 1 results after the bell Monday which showed that there was no clinically meaningful reduction in absorption for nine of the 12 drugs being tested when Veltassa was administered at the same time. The study was evaluating potential drug-drug interactions between Veltassa for oral suspension and 12 drugs that had previously demonstrated binding in in vitro tests.
Relypsa traded in a range throughout Monday's session and closed up by 0.01 at $19.62. The stock is now up 0.92 on 858K shares after the bell.
by RTT Staff Writer
http://www.rttnews.com/2603661/relypsa-inc-rlyp-is-climbing-on-phase-1-study-results.aspx
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM